VRF is proud to highlight a new patient support initiative launched by Incyte, named Opzelura On Trac. This program is designed for U.S. patients diagnosed with vitiligo who are prescribed Opzelura, providing essential support for those navigating the complexities of insurance coverage for their treatment.

Opzelura On Trac is distinguished by its financial assistance component, allowing qualified patients to significantly lessen their personal cost. Through a copay savings scheme, eligible participants may reduce their expenses to potentially $0 for each tube of Opzelura, which normally costs upwards of $2,000 for a 60-g tube. Additionally, IncyteCARES Patient Assistance Program exists to provide further financial aid to those in need.

Beyond financial support, the initiative equips patients with a comprehensive set of resources aimed at improving their understanding and management of vitiligo. This includes a dedicated application to assist patients through their treatment journey and an extensive FAQ section addressing common queries and concerns regarding JAK inhibitor treatments. For more information, visit OpzeluraOnTrac.com.

The VR Foundation continues its commitment to spotlighting innovative solutions and support mechanisms that contribute to vitiligo research, treatment, and comprehension. We encourage you to explore such resources as part of your holistic vitiligo management strategy.